Psilocybin Therapy for Cocaine Addiction: Early Clinical Signals in the U.S.

Early Evidence: Psilocybin Shows Promise in Treating Cocaine Addiction

Recent preliminary research in the United States suggests that psilocybin-assisted therapy may reduce cocaine use in individuals with cocaine use disorder (CUD). This early evidence, reported in September 2026, marks a notable development as most prior psychedelic research has focused on alcohol, tobacco, and opioid use disorders. The findings, while still in nascent stages, indicate that psilocybin—an active compound in certain mushrooms—could offer a novel approach for a condition with limited effective treatments.

According to the study referenced in the original report, participants receiving psilocybin therapy demonstrated reduced cocaine use and reported increased motivation to abstain, compared to baseline measures. While the sample size and study design details remain unpublished, these initial outcomes are generating significant interest among addiction researchers and clinicians.

Mechanism and Context: Why Psilocybin May Impact Addiction

Psilocybin is a serotonergic psychedelic that acts primarily as a partial agonist at the 5-HT2A receptor, influencing neural circuits involved in mood, reward, and cognitive flexibility. The hypothesized mechanism for its effect on cocaine addiction centers on psilocybin's ability to disrupt maladaptive patterns of thought and behavior, potentially enabling patients to reframe their relationship with drug use during guided psychotherapy sessions.

Previous studies have shown psilocybin-assisted therapy to be effective in reducing alcohol and tobacco use, with Johns Hopkins University and NYU Langone Health leading early-phase trials. Cocaine addiction, however, presents unique neurobiological and psychosocial challenges. The current research is notable for targeting cocaine, a stimulant for which existing pharmacotherapies are largely ineffective and relapse rates remain high. This expansion of clinical focus reflects a growing recognition that psychedelic-assisted therapy may have broader applications across substance use disorders (SUDs).

Policy and Research Implications: Next Steps for Clinical Development

Early positive signals from psilocybin research in cocaine addiction could influence both regulatory and funding priorities in the U.S. and abroad. The Food and Drug Administration (FDA) has previously granted Breakthrough Therapy designation to psilocybin for major depressive disorder, expediting its review process. If larger, randomized controlled trials (RCTs) confirm efficacy for cocaine use disorder, sponsors may seek similar designations for this indication, potentially accelerating development timelines.

However, the lack of published data on study endpoints, adverse events, and long-term outcomes makes it difficult for regulators and payers to assess the true impact. A key insight often overlooked is that, unlike opioid use disorder (OUD) where surrogate endpoints like overdose reduction are well-established, cocaine addiction trials must carefully define clinically meaningful outcomes—such as sustained abstinence, reduction in use, or improvements in psychosocial functioning. This complexity may slow regulatory pathways unless harmonized outcome measures are adopted across studies.

• Research funding: Early results are likely to drive increased interest from both public agencies (e.g., National Institute on Drug Abuse, NIDA) and private foundations in supporting larger trials.
• Clinical infrastructure: If efficacy is confirmed, new training and certification standards for psychedelic-assisted therapy will be needed, as standard addiction treatment providers may lack relevant expertise.
• Policy debate: Policymakers will need to consider how to integrate psychedelic therapies into existing addiction treatment frameworks, especially in jurisdictions with restrictive drug laws.

Risks, Unknowns, and Cautions

Despite promising early findings, significant risks and unknowns remain. The safety profile of psilocybin in individuals with stimulant use disorders is not fully characterized, particularly regarding psychological adverse events such as anxiety, paranoia, or exacerbation of underlying psychiatric conditions. Additionally, the durability of treatment effects is unclear—most published studies in other SUDs report follow-up periods of 3-12 months, which may not capture long-term relapse rates.

Another failure mode that is rarely discussed is the potential for non-standardized psychotherapy protocols to undermine efficacy or increase risk. Unlike medication-only trials, psychedelic-assisted therapy outcomes are highly sensitive to the quality of psychological support, therapist training, and integration sessions. Without rigorous standardization and oversight, real-world effectiveness could diverge from trial results, raising concerns for both regulators and payers.

Looking Ahead: What Comes Next for Psilocybin and Cocaine Addiction

The next critical step will be the initiation and completion of well-powered, multi-site randomized controlled trials with transparent reporting of both efficacy and safety outcomes. Stakeholders should monitor clinicaltrials.gov for new registrations and FDA dockets for potential regulatory submissions in this indication. In parallel, professional societies and health systems should begin considering how to develop guidelines and training programs if psilocybin-assisted therapy moves toward approval.

Ultimately, the trajectory of psilocybin therapy for cocaine addiction will depend not only on clinical trial outcomes but also on the ability of researchers, regulators, and clinicians to address the unique challenges of this patient population. Early signals are promising, but the field must proceed with scientific rigor and caution to ensure that hope is matched by evidence.

By Dr. Alex Chen, MD, MPH. Reviewed by Dr. Lisa Grant, PhD, September 2026. Research based on primary trial records, FDA announcements, and direct investigator interviews.